BL1 COST-EFFECTIVENESS, VALUE OF INFORMATION, AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL COMPARED TO SUBCUTANEOUS TUMOR NECROSIS FACTOR (TNF) INHIBITORS AND METHOTREXATE IN THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN FINLAND
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71862-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)71862-9/fulltext
Title :
BL1 COST-EFFECTIVENESS, VALUE OF INFORMATION, AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL COMPARED TO SUBCUTANEOUS TUMOR NECROSIS FACTOR (TNF) INHIBITORS AND METHOTREXATE IN THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN FINLAND
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71862-9&doi=10.1016/S1098-3015(11)71862-9
First page :
A243
Section Title :
RESEARCH PODIUM ABSTRACTS
Open access? :
No
Section Order :
21